登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C14H13N3O4S2
化学文摘社编号:
分子量:
351.40
MDL number:
UNSPSC Code:
41116107
NACRES:
NA.24
产品名称
美洛昔康, United States Pharmacopeia (USP) Reference Standard
InChI
1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,19H,1-2H3,(H,15,16)/b13-11+
InChI key
DWMREKMVXIFPFM-ACCUITESSA-N
grade
pharmaceutical primary standard
API family
meloxicam
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
正在寻找类似产品? 访问 产品对比指南
Other Notes
可能适用相应的销售限制。
Analysis Note
这些产品仅供测试和化验使用。它们不适用于人类或动物，也不能用于诊断、治疗或治愈任何类型的疾病。
Application
美洛昔康USP参标准品，预期用途是USP规定的指定质量测试和检测。也用于USP各论，例如：
- 美洛昔康口服混悬液
- 美洛昔康片
General description
本产品按照发行药典的发行和规定提供。支持本产品的所有信息，包括安全数据表和任何产品信息传单，都是在发行药典的授权下开发和发布的。如需进一步信息和支持，请访问现行药典网站。
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Brian J Gates et al.
Expert opinion on pharmacotherapy, 6(12), 2117-2140 (2005-10-04)
The discovery of two distinct isoenzymes of COX has led to the development and clinical introduction of COX-2 inhibitors with increased selectivity onto the market. Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class, and is a preferential
Meloxicam--a safer NSAID?
Drug and therapeutics bulletin, 36(8), 62-64 (1999-01-07)
Shunsuke Hamada et al.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 35(5), 4561-4566 (2014-01-07)
This study aimed to determine the prevalence of β-catenin nuclear positivity as a prognostic factor in patients with desmoid tumors (DTs) treated with meloxicam, a cyclooxygenase-2 (COX-2) selective inhibitor. Between 2003 and 2012, consecutive 31 patients with extraabdominal, sporadic DTs
[Meloxicam: intramuscular administration in rheumatology].
E S Tsvetkova
Terapevticheskii arkhiv, 75(8), 96-97 (2003-10-03)
J Sternon et al.
Revue medicale de Bruxelles, 19(1), 29-32 (1998-04-29)
NSAID's are currently medications widely prescribed. Meloxicam is a new oxicam which has a low COX-2/COX-1 ratio, i.e. it has an inhibitory effect focused on the inflammatory proteins (COX-2) with relative saving of the homeostatic proteins (COX-1). This molecule has
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持